Efficacy of Esketamine Augmentation in Major Depressive Disorder
The Journal of Clinical Psychiatry May 26, 2020 George I. Papakostas, Naji C. Salloum, Rebecca S. Hock et al. 107 citations
Adjunctive intranasal esketamine is more effective than placebo for treating major depressive disorder. Pooling five randomized, double-blind trials with 774 patients, esketamine outperformed placebo on depression rating scale score change, response, and remission. The effect was statistically significant across different study samples and baseline antidepressant regimens. Esketamine appears to be an effective treatment strategy for patients who are treatment-resistant or acutely suicidal.